Partial Hold On Cortexyme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1)
BASEL (dpa-AFX) - Today s Daily Dose brings you news about temporary suspension of bluebird bio s gene therapy trials in sickle cell disease, Sesen Bio s regulatory catalyst for this year, partial hold on Cortexyme s open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer s disease, and expanded FDA approval of Novartis Entresto.
Read on.
1. Sickle Cell Disease Trial Blues For bluebird bio
Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company s LentiGlobin gene therapy trials for sickle cell disease were temporarily suspended after two cases of cancer were reported in study participants. ....

United States , Hong Kong , United Kingdom , Bacille Calmette Guerin , Novarti Entresto , Cortexyme Inc , Genetic Technologies Corp , Inhibrx Inc , Clene Inc , Diffusion Pharmaceuticals Inc , Akers Biosciences Inc , European Union , Neptune Wellness Solutions Inc , European Medicines Agency , Timber Pharmaceuticals Inc , Daily Dose , Sesen Bio , Cell Disease Trial Blues For , Suspected Unexpected Serious Adverse Reaction , Partial Hold On Cortexyme , Pharma Hits New , Diffusion Pharmaceuticals , Expanded Label , Bio To Face , Biologics License Application , Pseudomonas Exotoxin ,